ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

This fundamental study explores a novel cellular mechanism underlying the degeneration of locus coeruleus neurons during chronic restraint stress. The evidence supporting the overexpression of LC ...

The surprise discovery of a huge cloud of molecular gas — the stuff that forms stars — just 300 light-years away is opening up new ways to study the conditions that enable star birth. Such ...

LOUISVILLE, Ky., April 28, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK) (the “Company”), a provider of personal emergency response systems (PERS), health communication devices, and ...

The primary pathological features of Alzheimer's disease (AD) are the extracellular amyloid beta (Aβ) plaques resulting ... quality recombinant protein and antibody reagents and to being a ...

Some practitioners argue that method of treatment claims are easier to obtain for structure–function-defined antibodies, but recent USPTO prosecution histories show that these claims also face ...

The iRS platform technology was applied to determine the secondary structure distribution of αSyn in CSF. The iRS platform and the capture antibody’s performance were extensively characterized by the ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting several autoimmune diseases. The funding consists of a $30 million series ...

In summary, our study delineates a mechanism initiated by β-CTF that can induce synaptic degeneration in a cell-autonomous manner, thus extending beyond the scope of Aβ antibody-based therapies. In ...

Its mission is to develop novel cancer therapeutic agents for patients with high unmet medical needs. OBI-992 and OBI-902 are TROP2-targeted antibody-drug conjugates (ADCs) that carries a potent ...